Decitabine in combination with idarubicin within a modified busulfan/cyclophosphamide conditioning regimen for patients with advanced myelodysplastic syndrome: A prospective multicenter clinical cohort study

Chin Med J (Engl). 2024 May 5;137(9):1115-1117. doi: 10.1097/CM9.0000000000002963. Epub 2024 Feb 2.
No abstract available

Publication types

  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Azacitidine* / administration & dosage
  • Azacitidine* / therapeutic use
  • Busulfan* / administration & dosage
  • Busulfan* / therapeutic use
  • Cyclophosphamide* / administration & dosage
  • Cyclophosphamide* / therapeutic use
  • Decitabine* / administration & dosage
  • Decitabine* / therapeutic use
  • Female
  • Humans
  • Idarubicin* / administration & dosage
  • Idarubicin* / therapeutic use
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes* / drug therapy
  • Prospective Studies
  • Transplantation Conditioning / methods
  • Young Adult

Substances

  • Busulfan
  • Cyclophosphamide
  • Decitabine
  • Azacitidine
  • Idarubicin